The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease
about
FGF-1 induces expression of LXRalpha and production of 25-hydroxycholesterol to upregulate the apoE gene in rat astrocytesImpact of apolipoprotein E on Alzheimer's diseaseApoE promotes the proteolytic degradation of AbetaApolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer diseaseCyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative DiseasesEffect of LXR/RXR agonism on brain and CSF Aβ40 levels in ratsAllopregnanolone promotes regeneration and reduces β-amyloid burden in a preclinical model of Alzheimer's diseaseComment on "ApoE-Directed Therapeutics Rapidly Clear -Amyloid and Reverse Deficits in AD Mouse Models"ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice.Anti-Amyloid Effects of Small Molecule Aβ-Binding Agents in PS1/APP MiceAnti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.Retinoic acid isomers facilitate apolipoprotein E production and lipidation in astrocytes through the retinoid X receptor/retinoic acid receptor pathway.Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice.A second class of nuclear receptors for oxysterols: Regulation of RORalpha and RORgamma activity by 24S-hydroxycholesterol (cerebrosterol)The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.Increased expression of RXRα in dementia: an early harbinger for the cholesterol dyshomeostasis?Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 miceCrosstalk between thyroid hormone receptor and liver X receptor in the regulation of selective Alzheimer's disease indicator-1 gene expression.Modulation of ABCA1 by an LXR agonist reduces β-amyloid levels and improves outcome after traumatic brain injuryNuclear receptors in neurodegenerative diseases.MicroRNAs: a connection between cholesterol metabolism and neurodegeneration.HDL and cognition in neurodegenerative disorders.Apolipoproteins in the brain: implications for neurological and psychiatric disorders.Minireview: nuclear receptor regulation of osteoclast and bone remodeling.Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonistAn ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia.Nuclear receptors as therapeutic targets for Alzheimer's diseaseRNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.Apolipoprotein E promotes β-amyloid trafficking and degradation by modulating microglial cholesterol levels.Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors.Bexarotene-Activated Retinoid X Receptors Regulate Neuronal Differentiation and Dendritic Complexity.ABC Transporters and the Alzheimer's Disease Enigma.Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 MiceMechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease.Liver X receptor agonist treatment significantly affects phenotype and transcriptome of APOE3 and APOE4 Abca1 haplo-deficient miceLiver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson's disease.Expression profiling in APP23 mouse brain: inhibition of Abeta amyloidosis and inflammation in response to LXR agonist treatmentRole of ABC transporters in the pathogenesis of Alzheimer's diseaseNeuroprotection by cyclodextrin in cell and mouse models of Alzheimer diseaseMitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics
P2860
Q24312559-B3AF2CAE-08F2-4A76-B6F9-B6EB132846EDQ24567759-061DC3B8-E3A3-43A2-93F1-231F9B109FD2Q24651102-974AD880-9584-4A0D-88FB-32DBE21BFB65Q26858870-C93511F3-0618-4C3B-A2F9-D76C9C4F796CQ28071254-2F6E1A59-F8EB-4D77-9A2A-9A7AA3A5C84FQ28602802-766FCB42-DB18-427A-8C00-3EEDE09FB238Q28740634-05C9289A-98C0-421D-932F-3E707E4A88F2Q29013008-0A46B815-4937-4E0B-B06B-7E0C80517878Q30497102-ACE19774-815F-43ED-B467-3AFF389FAA77Q33616714-DD2BE736-88C8-4634-A571-BCE757D66053Q33639513-9A9DDB0F-C039-48AB-9A7B-0BF8F9A9FB3BQ33676328-B5A0BFAC-B531-4AD1-A7AE-F9ABAA7F0C63Q33906674-FE264D54-47F7-434E-89EF-DF4297A7FB10Q33915348-7DC74917-621C-4CCD-8E3C-DEDEC39246D7Q33924208-7D73C7BC-23F6-4C6B-A3EC-03587BBDDE57Q34174694-E6A1FBD9-262E-4977-9EDE-BE4EB5CA7219Q34299304-BC98B4DA-763A-4527-BCB6-612148A7705EQ34566203-67571365-A338-41F0-99D5-81A724D19FBAQ34569187-7F17C671-7324-4967-ACB9-3E95AE718AC4Q34580020-C26494F3-9F6B-4CF4-A4B5-86C7B487E03AQ34613640-EC22C640-7BD3-4DA4-8ABF-C1326CB699BAQ34614842-054F1EC7-A683-4DF4-AE2C-5A8FC74BA066Q34680878-243C1054-9AEA-47CC-875E-E8AAE0A53688Q35054970-3FFF12B0-45CE-4F33-A302-99BA314E41E5Q35137114-83AA5BD2-5115-40D8-A8EB-98D941C91C50Q35152189-53779856-2DEC-4CD1-8F30-7E74F5B8188AQ35165186-B3D12D8A-99B1-4A6C-A2FE-B4C6ECB0E80FQ35662879-5B96B299-C96E-450E-A141-E44FED7A76D5Q35694025-0A9A5FD6-CBEC-44A5-8520-2F4D71DBEB7AQ35839729-E3B26C49-579D-4A3F-A502-80F5F3D6F2EFQ35995939-F79DEE22-4911-48BE-8109-00FF7968826AQ36005085-15DD4346-7F7E-42D3-A8E7-75811E8E5198Q36065117-B7986AC2-FFE8-40BD-8994-8A28E2CB0110Q36208400-D2AE7CE6-C2A4-4EB3-8043-9878BD5D919FQ36291665-DE9C93E5-7012-4CD9-B1FB-E0002C67B37EQ36332025-D21FC497-4B73-4A4A-8845-5FFAE61D0810Q36407043-49240F09-D8E1-4A69-A578-C9BB3B92999CQ36418108-01072203-03AB-4133-AE40-34E421B2388BQ36478244-0F2F6701-0FA8-47B7-A72B-7393588338C9Q36626374-87E6B277-DA15-41CA-8929-6FABD2676859
P2860
The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@ast
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@en
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@nl
type
label
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@ast
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@en
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@nl
prefLabel
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@ast
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@en
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@nl
P2093
P50
P3181
P356
P1476
The liver X receptor ligand T0 ...... e model of Alzheimer's disease
@en
P2093
Darren Wolfe
Iliya M Lefterov
John S Lazo
Joseph C Glorioso
Michael Walter
Shaohua Huang
P304
P3181
P356
10.1074/JBC.M411420200
P407
P577
2004-11-22T00:00:00Z